Codexis (NASDAQ:CDXS – Get Free Report)‘s stock had its “overweight” rating reaffirmed by analysts at Stephens in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $5.00 price target on the biotechnology company’s stock. Stephens‘s price objective indicates a potential upside of 367.29% from the stock’s current price.
CDXS has been the subject of a number of other research reports. Benchmark restated a “hold” rating on shares of Codexis in a report on Thursday, August 20th. Wall Street Zen upgraded Codexis from a “sell” rating to a “hold” rating in a report on Saturday. Piper Sandler decreased their price objective on Codexis from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Monday, August 17th. Finally, Weiss Ratings upgraded Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.00.
Check Out Our Latest Stock Analysis on CDXS
Codexis Price Performance
Codexis (NASDAQ:CDXS – Get Free Report) last issued its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. The company had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.72 million. Codexis had a negative net margin of 21.77% and a negative return on equity of 43.24%. Sell-side analysts anticipate that Codexis will post -0.37 earnings per share for the current year.
Institutional Trading of Codexis
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its holdings in shares of Codexis by 93.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 840,866 shares of the biotechnology company’s stock worth $1,169,000 after acquiring an additional 405,942 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Codexis during the 3rd quarter worth approximately $160,000. Private Advisor Group LLC acquired a new stake in Codexis in the 3rd quarter valued at approximately $1,677,000. Aberdeen Group plc increased its holdings in Codexis by 59.5% in the 3rd quarter. Aberdeen Group plc now owns 10,797,702 shares of the biotechnology company’s stock valued at $15,009,000 after purchasing an additional 4,027,748 shares during the last quarter. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in Codexis in the 3rd quarter valued at approximately $556,000. 78.54% of the stock is currently owned by hedge funds and other institutional investors.
About Codexis
Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.
Recommended Stories
- Five stocks we like better than Codexis
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.
